Blog

BenevolentAI wins Innovation Award at 2020 Scrip Awards

BenevolentAI has been selected by an eminent panel of global industry executives as the winner of the Innovation Award at the prestigious 2020 Scrip Awards.

The Innovation Award acknowledges and celebrates ‘Outstanding scientific or technological breakthroughs that have the potential to be transformative in the discovery or development of new medicines’. This Award follows a momentous year for BenevolentAI and is a testament to our COVID-19 research, the unrivalled strength of our Knowledge Graph and AI models, and the early success of our collaboration with AstraZeneca. 

Our COVID-19 research began in late January and advanced from hypothesis to FDA approval in nine months. Our team identified baricitinib as a potential treatment for COVID-19 in a time frame that would have been impossible to replicate without our sophisticated biomedical knowledge graph and artificial intelligence. In October, clinical data from the NIAID ACTT-2 trial validated our initial hypothesis, and baricitinib was subsequently given emergency approval by the FDA in November.  

This year, our platform also excelled in a collaboration environment: in April 2020, eight months into our partnership with AstraZeneca, we delivered the first output of hypotheses for CKD. Our two teams quickly became one, working closely together to generate a knowledge graph enhanced on CKD and applied AI and ML models to generate a set of targets predicted to be most useful in treating CKD. 

The application of artificial intelligence to drug discovery is unrivalled in its complexity, and we are honoured to have our pioneering work in this field recognised at the Scrip Awards. This year demonstrated the power, scalability and adaptability of our AI-augmented end-to-end drug discovery and development approach. Next year, and for years to come, we will continue our mission to unite human and artificial intelligence to translate data into life-changing medicines which help patients live healthier, happier lives.


More Posts

You Might Also Like

Blog
Transforming drug discovery with AI: how we’re building and nurturing the best talent for the job
At BenevolentAI, we are on a mission to bring life-changing medicines to patients, and we are looking for collaborative, mission-driven people to join our tech, drug discovery and business operations teams in London, Cambridge and New York.
Oct 17, 2021
News
BenevolentAI identifies novel target for ulcerative colitis and advances candidate to IND/CTA-enabling studies
BenevolentAI’s AI-Drug Discovery platform uncovered a novel target not previously linked to ulcerative colitis and advanced candidate to preclinical studies.
Oct 14, 2021
Blog
Measuring bias: moving towards more inclusive health research outcomes #stateofai
Having shared our open-source Diversity Analysis Tool last year, we were tasked to investigate and demonstrate the lack of diversity in biomedical data as part of the State of AI Report 2021.
Oct 12, 2021
Blog
Expert-augmented computational drug discovery for rare diseases
Combining scientific expertise, computational tools and our AI-enhanced biomedical knowledge graph to successfully uncover a new drug combination for treating a rare brain cancer in children.
Sep 28, 2021
News
BenevolentAI appoints Dr John Orloff to its Board of Directors
Biopharmaceutical veteran Dr John Orloff joins the BenevolentAI Board as a Non-Executive Director as it scales the development of its leading AI-derived drug pipeline.
Sep 9, 2021
Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021